Arvinas (ARVN) Equity Income (2019 - 2020)

Arvinas (ARVN) posted quarterly Equity Income of -$1.4 million for Q2 2020, down 227.27% quarter-over-quarter from $1.1 million in Q1 2020.

Arvinas (ARVN) Equity Income (2019 - 2020) Analysis & Trends

Arvinas' Equity Income history runs 2 years deep, the most recent figure standing at -$1.4 million for Q2 2020.

In Q2 2020, Equity Income changed N/A year-over-year to -$1.4 million; the TTM figure through Jun 2020 stood at $49.5 million (changed N/A YoY), while the FY2019 annual figure was $49.8 million, changed N/A from the prior year.
Equity Income for Q2 2020 stood at -$1.4 million, down from $1.1 million in the prior quarter.
The five-year high for Equity Income was $99.3 million in Q4 2019, with the low at -$49.5 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Arvinas	585.74 Mn	17.84 Mn	-	-

Download Data